For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Turning Point Therapeutics, Inc.

USPTO Granted Patents = 18

EPO Patents = 9

Trademarks = 5

Forward Citations = 21

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Jingrong Jean Cui (18 out of 44 patents)

Dayong Zhai (17 out of 21 patents)

Evan W Rogers (15 out of 44 patents)

4. Wei Deng (12 out of 13 patents)

5. Jane Ung (9 out of 18 patents)

6. Yishan Li (7 out of 10 patents)

7. Jeffrey Whitten (5 out of 5 patents)

8. Zhongdong Huang (5 out of 5 patents)

9. Han Zhang (5 out of 5 patents)

10. Xin Zhang (3 out of 4 patents)

11. Jing Liu (3 out of 25 patents)

12. Vivian Nguyen (2 out of 2 patents)

13. Brion William Murray (2 out of 10 patents)

14. Laura Rodon (2 out of 2 patents)

15. Nathan V Lee (1 out of 1 patent)

18 patents: Sort by Forward Citations

1. RE50634 - Diaryl macrocycles as modulators of protein kinases (2025-10-14),

2. 12404281 - Diaryl macrocycles as modulators of protein kinases (2025-09-02),

3. 12310968 - Chiral diaryl macrocycles and uses thereof (2025-05-27),

4. 12187739 - Diaryl macrocycle polymorph (2025-01-07),

5. 11981684 - Macrocyclic compounds and uses thereof (2024-05-14),

6. 11666574 - Combination therapy involving diaryl macrocyclic compounds (2023-06-06),

7. 11654145 - Combination therapy involving diaryl macrocyclic compounds (2023-05-23),

8. 11634433 - Macrocycles for use in treating disease (2023-04-25),

9. 11452725 - Chiral diaryl macrocycles and uses thereof (2022-09-27),

10. 11291667 - Combination therapy involving diaryl macrocyclic compounds (2022-04-05),

11. 11286265 - Macrocyclic compounds for treating disease (2022-03-29),

12. 11286264 - Macrocyclic compounds and uses thereof (2022-03-29),

13. 11155563 - Macrocyclic compounds and uses thereof (2021-10-26),

14. 11142533 - Macrocycles for use in treating disease (2021-10-12),

15. 11008337 - Chiral diaryl macrocycles as modulators of protein kinases (2021-05-18),

Turning Point Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. Their goal is to develop small molecule targeted therapies to address the limitations of existing treatments. Their approach is to identify specific genetic alterations that drive cancer growth and create therapies that effectively target and inhibit those mechanisms. Through their innovative research and development efforts, Turning Point Therapeutics aims to deliver transformative therapies to improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#309 in San Diego, CA

#4,156 in California

#17,414 in US

#33,186 in the World

San Diego, CA, United States of America

Turning Point Therapeutics, Inc.

Forward Citations = 21

15 inventors:

Jingrong Jean Cui (18 out of 44 patents)

Dayong Zhai (17 out of 21 patents)

Evan W Rogers (15 out of 44 patents)

4. Wei Deng (12 out of 13 patents)

5. Jane Ung (9 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…